Side-by-side comparison of AI visibility scores, market position, and capabilities
British consumer health company with £14B revenue; Lysol, Mucinex, Nurofen, and Durex brands managing Mead Johnson infant formula litigation while competing with P&G and J&J.
Reckitt is a British multinational consumer health and hygiene company producing market-leading brands including Nurofen (ibuprofen), Strepsils, Dettol, Lysol, Durex, Mucinex, Enfamil infant formula, and Woolite — competing across OTC health, hygiene and home, and nutrition categories. Listed on the London Stock Exchange (LSE: RKT) and headquartered in Slough, England, Reckitt generates approximately £14 billion ($17 billion) in annual revenue. The company has undergone significant portfolio reshaping, divesting its Infant Formula & Child Nutrition (IFCN) business in some markets and selling Mead Johnson Nutrition operations.\n\nReckitt's business is organized into two segments: Health (Nurofen, Strepsils, Gaviscon, Mucinex, DayQuil/NyQuil in North America) and Hygiene and Home (Lysol/Dettol disinfectants, Finish dishwasher tablets, Vanish stain remover, Air Wick). The Health segment benefits from strong brand equity in OTC medications that command premium pricing. The Hygiene segment's Lysol brand benefited significantly from COVID-19 disinfectant demand and has sustained elevated brand awareness post-pandemic.\n\nIn 2025, Reckitt faces ongoing challenges from its $2.4 billion acquisition of Mead Johnson (Enfamil) — the company has faced significant litigation related to NEC (necrotizing enterocolitis) lawsuits claiming preterm infant formula contributed to infant deaths, resulting in large court judgments against Reckitt in 2024. The company is managing these legal liabilities while continuing to run its core consumer health and hygiene portfolio. Reckitt competes with Procter & Gamble, Johnson & Johnson, and Haleon for OTC health and hygiene market share. The 2025 strategy focuses on its Power Brands in health and hygiene, cost efficiency, and resolving the Mead Johnson litigation exposure.
Hershey PA chocolate and snacks (NYSE: HSY) ~$10.2B FY2024 revenue; Reese's #1 US candy brand, cocoa inflation $2.5K→$12K/MT crisis, SkinnyPop salty snacks, competing with Mars and Ferrero.
The Hershey Company is a Hershey, Pennsylvania-based confectionery and snacks company — publicly traded on the New York Stock Exchange (NYSE: HSY) as an S&P 500 Consumer Staples component — manufacturing and selling chocolate, candy, mints, gum, and salty snacks through iconic brands including Hershey's (chocolate bars, Kisses), Reese's (peanut butter cups — America's #1 candy brand by revenue), Kit Kat (licensed from Nestlé for the US market), York Peppermint Patties, Jolly Rancher, Ice Breakers, Skinny Pop, Dot's Pretzels, and Pirate's Booty through approximately 18,000 employees in 80+ countries. In fiscal year 2024, Hershey reported net sales of approximately $10.2 billion, with earnings per share significantly compressed by unprecedented cocoa commodity inflation: West African cocoa prices (Ghana and Ivory Coast provide 70%+ of global cocoa supply) surged from $2,500/metric ton in 2022 to over $12,000/metric ton in early 2024 — the highest prices in 50+ years — driven by El Niño-related drought and crop disease (swollen shoot disease) reducing cocoa harvests, creating a chocolate manufacturer cost crisis that Hershey absorbed through price increases and hedging while managing volume declines as consumers resisted higher candy prices. CEO Michele Buck has guided Hershey through the cocoa inflation crisis by implementing 10-15% retail price increases in 2023-2024, reformulating some lower-margin products to reduce cocoa content, and hedging cocoa commodity exposure on a rolling 12-18 month forward basis to smooth out extreme spot price volatility.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.